369 F. Supp. 2d 876 - Cartwright v. Pfizer, Inc.’s Empirical Analysis
2005
Citation profile
2 district · 4 state decisions
Relationships
Applies 21 U.S.C. § 360K (Federal Food, Drug, and Cosmetic Act)
Relies on Anderson v. Liberty Lobby, Inc. · Celotex Corporation v. Catrett H · Medtronic, Inc. v. Lohr · Fidelity Federal Savings and Loan Association v. D Cuesta · Hillsborough County v. Automated Medical Laboratories, Inc.
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 12 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling thereof,”
1 later decision quote this exact passage · from the majoritye.g. Levine v. Wyeth“With little exception, courts that have considered this exact issue have concluded that state failure to warn claims are not preempted by the FDCA and its attendant regulations.”
1 later decision quote this exact passage · from the majoritye.g. Levine v. Wyeth“based on a fair evaluation of all material facts, such labeling is false or misleading in any particular.”
1 later decision quote this exact passage · from the majoritye.g. Levine v. Wyeth
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.